Project Grant RF1AG073210
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $476,993 to Yale University to develop new methods for measuring white matter hyperintensities (WMH) using low-field portable MRI (PMRI) technology. The project aims to create both a qualitative WMH grading scale and a quantitative machine learning-based WMH volume...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded the University of Pittsburgh a $2.0 million Project Grant (CFDA 93.866, Aging Research program) effective September 15, 2025, through August 31, 2029, to conduct research characterizing white matter injury in Alzheimer's disease (AD). The project will investigate risk factors and consequences of white matter injury in brain regions affected by AD pathology using a novel measurement methodology called Unhealthy...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
- Federal Grant Award Summary The National Institute on Aging has awarded Massachusetts General Hospital a $1.341 million Project Grant under the Aging Research program (CFDA 93.866) to develop advanced high-resolution magnetic resonance imaging (MRI) methods for analyzing cerebrospinal fluid (CSF) dynamics and waste clearance in Alzheimer's disease. The award, effective April 15, 2026 through March 31, 2031, supports research aimed at optimizing MRI technology to noninvasively track CSF flow...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a pilot study to evaluate the feasibility of using non-invasive neuroimaging techniques to monitor the metabolic and vascular functions of the brain and heart in a mouse model of Alzheimer's disease (AD). The $332,096 award, with a performance period from July 2024 to June 2026, will be made to The General Hospital Corporation (doing business as Massachusetts General Hospital). The research...
- Grant Award Summary The University of Pittsburgh received a $664,619 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) effective January 1, 2026, through December 31, 2030. This award funds comprehensive research into multiscale models of age-specific neurometabolic coupling, addressing a critical gap in understanding the relationship between cognitive function and brain metabolic processes, particularly in late-onset Alzheimer's disease. The research...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital a $684,567 Project Grant on March 1, 2026, under the Aging Research program (CFDA 93.866) to support a four-year methodology research initiative examining the utility of 64-copper-fibrin-binding-probe-8 positron emission tomography (64Cu-FBP8 PET) for detecting and quantifying pathological fibrin in the brain. The research will evaluate in vivo pharmacokinetics of the fibrin-binding probe...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...
- The National Institute on Aging (NIA) awarded a $454,024 Project Grant (CFDA 93.866 - Aging Research) to the Research Foundation For Mental Hygiene, Inc. (RFMH) to conduct research on high-frequency oscillations (HFOs) as a potential biomarker for Alzheimer's disease progression. The key goals of this 2-year project are to: (1) determine if HFOs originate in the hippocampus and expand to other brain regions as Alzheimer's pathology advances, (2) assess whether disrupting HFOs can improve...
- This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
WHITE MATTER METABOLISM IN THE CONTEXT OF AGING, WHITE MATTER HYPERINTENSITIES AND ALZHEIMER'S DISEASE - ABSTRACT WHITE MATTER HYPERINTENSITIES (WMH) ARE UBIQUITOUS IN THE AGING BRAIN. PREVAILING THEORIES IMPLICATE ARTERIOSCLEROSIS AND ENDOTHELIAL DYSFUNCTION FOLLOWED BY ISCHEMIC AND HYPOXIC INJURY AS A CAUSE, BUT FACTORS THAT RESIST OR MODIFY THESE MECHANISMS ARE UNKNOWN. ANIMAL STUDIES SHOW THAT GLYCOLYSIS IS A PRINCIPAL METABOLIC FEATURE OF NORMAL WHITE MATTER AND PROTECTIVE AGAINST MITOCHONDRIAL FAILURE. HOWEVER, WHITE MATTER GLYCOLYSIS HAS BEEN UNDERSTUDIED IN IN VIVO HUMAN STUDIES AND PARTICULARLY IN THE CONTEXT OF WMH. OUR LABORATORY HAS DEVELOPED METHODS, NOW ON A STATE-OF-THE-ART PET SCANNER, TO QUANTITATIVELY MEASURE BRAIN GLYCOLYSIS USING MULTIPLE RADIOTRACERS, INCLUDING 15O RADIOTRACERS TO MEASURE CEREBRAL OXYGEN CONSUMPTION (CMRO2), CEREBRAL BLOOD FLOW (CBF) AND OXYGEN EXTRACTION FRACTION (OEF), AND 18FDG TO MEASURE TOTAL GLUCOSE USE (CMRGLC), FROM WHICH WE CAN DERIVE THE RATE OF AEROBIC GLYCOLYSIS (AG). HERE WE PROPOSE TO APPLY THESE METHODS TO PROVIDE GOLD-STANDARD QUANTITATIVE ESTIMATES OF NORMAL HUMAN WHITE MATTER METABOLISM, AND TO SPECIFICALLY INVESTIGATE WHITE MATTER GLYCOLYSIS IN THE CONTEXT OF WMH. IN OUR FIRST TWO AIMS, WE WILL COMPARE THE TOPOGRAPHY OF METABOLIC PET MEASUREMENTS TO MRI MEASUREMENTS OF WHITE MATTER MICROSTRUCTURE AND WMH, BOTH IN HEALTHY ADULTS WITHOUT WMH AND IN ADULTS WITH WMH. IN OUR THIRD AIM, WE WILL ANALYZE LONGITUDINAL MRI IMAGING DATA IN A COHORT OF ADULTS WHO HAVE ALREADY UNDERGONE METABOLIC PET IN OUR PRIOR AND ONGOING STUDIES ON AN OLDER SCANNER, TO TEST THE HYPOTHESIS THAT RELATIVE DIFFERENCES IN WHITE MATTER GLYCOLYSIS WILL PREDICT SUBSEQUENT WMH DEVELOPMENT AND PROGRESSION. MOREOVER, WE WILL EXPLORE POTENTIAL RELATIONSHIPS BETWEEN NEURODEGENERATIVE PATHOLOGY AND WMH, WHICH WE HYPOTHESIZE OCCURS DUE TO EFFECTS OF THE AFOREMENTIONED PATHOLOGY ON WHITE MATTER METABOLISM, THEREBY REDUCING ITS RESILIENCE TO WMH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/25/25 | ||
| Not listed | $2.3m | 4/29/22 | ||
| Not listed | $2.3m | 4/29/22 |